Active Stocks on Frontline- Pengrowth Energy (NYSE:PGH), Amicus Therapeutics (FOLD), Hologic (HOLX)

Pengrowth Energy Corporation (NYSE:PGH) jumped down turns in hot stance in regular session as it -7.23% to $1.54 in the session with shares volume of 1.2 Million. Pengrowth Energy (PGH) declared that it sells a non-convertible gross overriding royalty interest on its Lindbergh thermal property for $250 million cash consideration. Under the terms of the contract, Pengrowth is selling a 4.0% royalty on all of its Lindbergh thermal properties, including existing production from the first commercial phase as well as production from future development phases, including its Muriel Lake lease.

As part of the contract, the purchaser of the royalty retains the option to receive the royalty either in cash or as production in kind.Included with the sale is a working interest in certain of Pengrowth’s proprietary seismic data.Included with the sale is a working interest in certain of Pengrowth’s proprietary seismic data.

What made Pengrowth Energy Corporation to beat analysts’ forecasts in this rally? Find Out Here

Amicus Therapeutics, Inc. (NASDAQ:FOLD) tries to make charm in street, as shares traded at $5.85 with rises of 0.52% in last trading session. Amicus Therapeutics (FOLD) declared that an offering of $225 million convertible senior notes due 2023 in a private placement. The firm intends to offer $225 million aggregate principal amount of convertible senior notes due 2023 in a private placement.

The offering is subject to market conditions, and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering. The notes will be senior unsecured obligations of Amicus with interest payable semi-annually. The notes may be converted into cash, common stock or a combination of both. Amicus intends to use a portion of the proceeds to refinance existing unsecured debt and to fund the cost of the capped call transactions with the remaining being used for general corporate purposes. While past twelve months price to sales ratio recorded as 391.88 and price to cash ratio remained 3.87.

Why Amicus Therapeutics, Inc. entered oversold zone after this report? Find Out Here Totally Free

Shares of Hologic, Inc. (NASDAQ:HOLX) moved up 0.67% to finish at $40.79 in last run as Hologic (HOLX) aims to sell blood screening business to Grifols (GRFS) for $1.85 billion in cash; will update FY17 guidance after the transaction closes HOLX is halted. Under the contract, Grifols will receive a fully paid-up license to certain of Hologic’s intellectual property for use in the blood screening field.

Approximately 175 people, mainly in operations and research and development, will transfer to Grifols, along with Hologic’s blood screening manufacturing facility in Rancho Bernardo, California. Hologic will retain the engineering expertise that led to the development of the fully automated TIGRIS and Panthersystems, but will partner with Grifols to ensure that blood screening consumers continue to benefit from instrumentation over the long term.

Looking toward firm’s returns performance, it has return on equity of 15.80% and returns on assets was calculated 4.50% with 4.73% year to date performance. The annual sales growth for the past five year was 9.60%.

How Hologic, Inc. attracted investors to get BUY rating after this bullish run? Find Facts Here


About Richard Avery

He is a capital projects manager and process design engineer at a large-cap company. He has renowned MBA degree. Before joining SWR, he was a freelance writer for renounce tech websites. He is currently studying for CFP exam. Interests: Tech stocks, Economic Markets, Blue-chips.

Leave a Reply

Your email address will not be published. Required fields are marked *